Mr. Martin Helbo Behrens serves as CEO at ChemoMetec A/S since March 13, 2024. He is Chief Operating Officer of ChemoMetec A/S from December 2023. He was Vice Chief Operating Officer of ChemoMetec A/S from...

리더십 팀

이름	위치	테뉴어	보상	소유권
Hans Glensbjerg	Senior Advisor	less than a year	DKK 20.00k	0.27% DKK 14.2m
Martin Behrens	CEO & COO	less than a year	데이터 없음	데이터 없음
Niels Nielsen	Chief Financial Officer	1.7yrs	데이터 없음	0.0052% DKK 271.2k
Christopher Runchel	Chief Sales Officer	no data	데이터 없음	데이터 없음
Marta Planaguma	Chief Marketing & Strategy Officer	less than a year	데이터 없음	데이터 없음
Lisbet Helles	Head of Marketing	less than a year	데이터 없음	데이터 없음
Søren Kjærulff	Head of R&D	no data	데이터 없음	데이터 없음
Kenneth Paustian	Head of Finance	1.5yrs	데이터 없음	데이터 없음
Bo Nielsen	Chief R&D Officer and Physicist & Project Manager	less than a year	데이터 없음	데이터 없음

0.6yrs

평균 재임 기간

경험이 풍부한 관리: CHEMM 의 관리팀은 경험 (평균 재직 기간 0.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Peter Reich	Independent Director	9.8yrs	DKK 40.00k	0.0083% DKK 436.9k
Kristine Faerch	Independent Director	3.8yrs	데이터 없음	0.00032% DKK 16.8k
Niels Thestrup	Chairman	2.8yrs	데이터 없음	0.011% DKK 587.5k
Betina Hagerup	Independent Director	2.8yrs	데이터 없음	0.0017% DKK 88.1k

3.3yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: CHEMM 의 이사회는 경험(평균 재직 기간 3.2 년)으로 간주됩니다.

ChemoMetec 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

ChemoMetec A/S Announces CFO Changes

Independent Director recently bought kr.450k worth of stock

ChemoMetec A/S Announces CEO Changes

ChemoMetec A/S Announces Executive Changes

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

Recent updates

What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

ChemoMetec A/S Announces CFO Changes

Independent Director recently bought kr.450k worth of stock

Investor sentiment improves as stock rises 17%

Now 20% overvalued

Price target increased by 14% to kr.513

Now 21% overvalued

Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%

ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24

Investor sentiment deteriorates as stock falls 18%

Investor sentiment deteriorates as stock falls 16%

ChemoMetec A/S Announces CEO Changes

What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You

What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?

Investor sentiment improves as stock rises 30%

Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First half 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

ChemoMetec A/S Maintains Earnings Guidance for the Year 2024

Price target decreased by 18% to kr.448

ChemoMetec A/S Announces Executive Changes

Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Investor sentiment improves as stock rises 30%

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Investor sentiment improves as stock rises 17%

Upcoming dividend of kr.6.00 per share at 1.8% yield

ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

Chemometec A/S Proposes Dividend for the 2022/23 Financial Year

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Financial data availability

ChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024

At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023

First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022)

Investor sentiment deteriorates as stock falls 20%

ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023

Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

Investor sentiment deteriorated over the past week

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23

If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021)

ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023

Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

ChemoMetec A/S, Annual General Meeting, Oct 12, 2023

Less than half of directors are independent

Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?

Upcoming dividend of kr.4.00 per share

Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020)

Here's Why I Think ChemoMetec (CPH:CHEMM) Might Deserve Your Attention Today

Here's Why I Think ChemoMetec (CPH:CHEMM) Might Deserve Your Attention Today

ChemoMetec A/S' (CPH:CHEMM) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

ChemoMetec (CPH:CHEMM) Is Growing Earnings But Are They A Good Guide?

First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020)

New 90-day high: kr.597

What Type Of Shareholders Make Up ChemoMetec A/S' (CPH:CHEMM) Share Registry?

New 90-day high: kr.566

Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?

New 90-day high: kr.461

ChemoMetec A/S' (CPH:CHEMM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Full year earnings released - EPS kr.3.51

New 90-day high: kr.403